Common copy number variations (CNVs) represent a significant source of genetic diversity, yet their influence on phenotypic variability, including disease susceptibility, remains poorly understood. To address this problem in human cancer, we performed a genome-wide association study of CNVs in the childhood cancer neuroblastoma, a disease in which single nucleotide polymorphism variations are known to influence susceptibility 1, 2 . We first genotyped 846 Caucasian neuroblastoma patients and 803 healthy Caucasian controls at ,550,000 single nucleotide polymorphisms, and performed a CNV-based test for association. We then replicated significant observations in two independent sample sets comprised of a total of 595 cases and 3,357 controls. Here we describe the identification of a common CNV at chromosome 1q21.1 associated with neuroblastoma in the discovery set, which was confirmed in both replication sets. This CNV was validated by quantitative polymerase chain reaction, fluorescent in situ hybridization and analysis of matched tumour specimens, and was shown to be heritable in an independent set of 713 cancer-free parentoffspring trios. We identified a previously unknown transcript within the CNV that showed high sequence similarity to several neuroblastoma breakpoint family (NBPF) genes 3, 4 and represents a new member of this gene family (NBPF23). This transcript was preferentially expressed in fetal brain and fetal sympathetic nervous tissues, and the expression level was strictly correlated with CNV state in neuroblastoma cells. These data demonstrate that inherited copy number variation at 1q21.1 is associated with neuroblastoma and implicate a previously unknown neuroblastoma breakpoint family gene in early tumorigenesis of this childhood cancer.
Neuroblastoma is a paediatric cancer of the developing sympathetic nervous system that most commonly affects young children, and is often lethal 5 . Most neuroblastomas arise sporadically, with less than 1% of cases inherited in an autosomal dominant fashion 5 . We recently identified the anaplastic lymphoma kinase (ALK) gene as the major hereditary neuroblastoma predisposition gene 1 . For the majority of neuroblastomas that arise without a family history of the disease, we hypothesize that multiple common DNA variations cooperate to increase the risk for neuroblastic malignant transformation. By performing a genome-wide association study (GWAS) of single nucleotide polymorphism (SNP) genotypes, we recently identified common SNP alleles within the putative FLJ22536 and FLJ44180 genes at 6p22 and within the BARD1 gene at 2q35 associated with malignant neuroblastoma, providing the first evidence that childhood cancers also arise owing to complex interactions of polymorphic variants 1, 2 .
Here we investigate constitutional DNA CNVs as another source of genetic diversity that may contribute to the development of this disease. CNVs have been shown to significantly influence messenger RNA expression levels 6 and recent studies have described associations of CNVs with systemic autoimmunity 7, 8 , autism 9 , schizophrenia [10] [11] [12] and psoriasis 13 . In addition, an increased number of CNVs in LiFraumeni families harbouring TP53 mutations has been reported, but the associations of individual CNVs with cancer susceptibility have not been explored 14 
.
To identify CNVs that are associated with neuroblastoma, we first genotyped a discovery set of 1,032 Caucasian neuroblastoma patients and 2,043 disease-free Caucasian control subjects, as previously described 1, 15 . We next applied stringent quality control criteria necessary for accurate CNV detection and reliable association assessment (see Supplementary Methods). The final discovery set consisted of 846 Caucasian cases and 803 Caucasian controls (Supplementary  Tables 1 and 2 ). These subjects showed tight clustering in a multidimensional scaling analysis of SNPs not in linkage disequilibrium ( Supplementary Fig. 1 ), demonstrating that population substructure was not likely to have a significant impact on association testing.
By comparing single marker binary copy number states at 531,689 SNPs mapped to autosomes, we observed a total of 131 SNPs showing significant association with neuroblastoma, defined as a two-sided Fisher's exact test P value below a genome-wide threshold of P 5 1.0 3 10 27 (Supplementary Table 3 ). Associations with deletion polymorphisms were seen at chromosomes 1, 7 and 14 (Fig. 1a) ; no duplication polymorphisms reached genome-wide significance (Fig. 1b) . Review of significant SNPs revealed four distinct regions of deletion (Table 1) . We next sought to validate significant association signals in two independent replication sets, the first consisting of 363 Caucasian cases and 1,139 Caucasian controls, and the second of 232 Caucasian cases and 2,218 Caucasian controls (Supplementary Tables  1 and 2 ). All deletion associations showed robust replication in both independent case series ( Table 2 and Supplementary Tables 4 and 5) .
We observed a seven-SNP deletion at 1q21.1 that occurred in 15.6% of cases but only 9.1% of controls overall (P combined 5 2.97 3 10
217
; odds ratio (OR), 2.49; 95% confidence interval (CI), 2.02-3.05). This association remained significant after additional adjustment for potential population substructure captured by SNPs not in linkage disequilibrium (P discovery , 0.0001), and was driven by a difference in hemizygous deletion frequency (P combined 5 1.83 3 10
219
). The observed frequency of homozygous deletion was identical in cases and controls (1.3% overall). The maximal deletion defined by neighbouring two-copy SNPs spanned 1.6 Mb and contained a cluster of NBPF genes (Fig. 1c) . To reduce the maximal deletion boundaries, we first genotyped 48 representative samples on the Illumina CNV-12 array (36 cases and 12 controls equally divided between those with and without the deletion CNV). These data refined the maximal size of the deletion to approximately 300 kb, consistent with published reports of CNVs at this location (Fig. 1c ) [16] [17] [18] . Finally, use of the Illumina HumanHap610 SNP platform reduced the maximal deletion size to only 143 kb, from 147,292,384-147,435,422 bp ( Supplementary  Fig. 2 ). The minimal deletion based on significant SNPs in the association study spanned 121 kb from 147,305,744-147,427,061 bp and did not contain any known genes (Fig. 1d) .
We next sought to confirm that this CNV is indeed a heritable genetic variation. First we genotyped an independent set of 713 trios from variable phenotypes on the same 550K SNP array and generated CNV calls using a family-based approach 16 . Deletion at 1q21.1 was observed in 125 offspring and confirmed by parental analysis in 123 trios, estimating the inheritance rate to be 98.4%. Next we genotyped paired tumour DNA in 226 cases (Supplementary Table 2 ) using the same 550K SNP platform, and confirmed existence of the CNV (deletion and duplication) in every tumour sample studied (Supplementary Fig. 3a) . We did not observe progression from hemizygous deletion in constitutional DNA to homozygous deletion . The BQ431323 melanoma EST maps uniquely within this region, whereas several GenBank transcripts align to the region with .95% identity but map elsewhere on the genome. BLAT alignment of PCR amplified and cloned sequence from fetal brain in this study is shown (NBPF23). in the matched tumour DNA for any case in this study, nor did we observe any expansion of CNV boundaries in the tumour compared to matched constitutional DNA.
To investigate whether 1q21.1 deletions are associated with specific neuroblastoma phenotypes, we tested each for association with clinical covariates using the combined set of 1,441 cases (Supplementary Table 6 ). Although deletions at 1q21.1 were observed more frequently in patients with aggressive disease, this trend did not reach statistical significance in this study. An additive effect on the odds ratio was observed for those harbouring both the 1q21.1 deletion and the 6p22 risk alleles ( Supplementary Fig. 4 ), but no significant interaction effect was detected to indicate epistasis (Supplementary Table 7 ).
In addition to the 1q21.1 CNV, we observed highly significant associations of deletion within all four T-cell receptor (TCR) loci clustered on chromosomes 7 and 14. Contrary to the 1q21.1 CNV, these deletions were not observed in paired tumour DNA samples ( Supplementary  Fig. 3b ). Heterogeneity was observed in the areas of apparent deletion, consistent with some cells harbouring homozygous deletion and others exhibiting two-copy heterozygosity. Deletions within different TCRs tended to co-occur in patients (P , 0.0001, Supplementary Table  7) , and were significantly more common in blood-than bone-marrowderived DNA samples (P TRG 5 9. ). Taken together, these findings indicate that we are detecting an oligoclonal expansion of T-cell lymphocytes in a subset of neuroblastoma patients, and this signal is diluted within the bone marrow compartment. Interestingly, TCR deletions showed a marked over-representation in the less aggressive subset of neuroblastoma (Supplementary Table 6 and Supplementary Fig. 5 ). It is possible that these events herald an immunologic response to neuroblastoma; however, this hypothesis requires further investigation.
To validate the 1q21.1 CNV, we first performed quantitative polymerase chain reaction (qPCR) on 46 neuroblastoma cases (10 zerocopy, 16 one-copy, 12 two-copy and 8 duplications as predicted by SNP analysis). We observed 100% concordant results when comparing copy number estimated by qPCR with copy number based on SNP genotyping (Fig. 2a) . To confirm that the detected CNV is not an artefact caused by segmental duplication of the 1p36 region, and that it indeed maps to 1q21.1, we validated the existence of the deletion in a sample harbouring a single-copy loss using fluorescent in situ hybridization (Fig. 2b) .
Although no known genes mapped to the refined 1q21.1 CNV, we identified a spliced EST (BQ431323) from a melanoma library that mapped within the CNV with 100% identity across the entire sequence (Fig. 1d) . Using primers designed against exon 1 and exon 3 of BQ431323, we PCR-amplified complementary DNA from fetal brain and a neuroblastoma cell line. These PCR products were cloned and sequenced (GenBank accession number GQ131873); the resulting sequence mapped uniquely within the CNV with 100% identity across the entire sequence and showed splicing out of the predicted second exon of BQ431323 ( Supplementary Fig. 6 ). The top scoring hit from a Blastn 19 search of this sequence against available human RefSeq transcripts was NBPF3 (E 5 5.0 3 10 289 ), followed by NBPF1 (E 5 1.0 3 10
275
) and NBPF15 (E 5 2.0 3 10
224
). These data provide strong evidence for a new NBPF transcript, named NBPF23 here, mapping within the 1q21.1 CNV associated with neuroblastoma.
We investigated the expression of NBPF23 in both neuroblastoma cells and normal human fetal and adult tissues using real-time quantitative reverse transcriptase PCR. Analysis of 18 neuroblastomas (tumours and cell lines) of known copy number at the 1q21.1 CNV showed a clear correlation between CNV state and transcript expression (Fig. 2c) . Notably, two-copy samples clustered into two distinct expression classes (P 5 0.007), the first with low expression and the second with high expression, and these probably represent different 1q21.1 CNV genotypes. There are two possible CNV genotypes for two-copy samples, which we refer to as 2:0 ('cis') and 1:1 ('trans') based on the number of copies present on each chromosome in a diploid genome (Supplementary Fig. 7a ). Two neuroblastoma samples in the low-expression group can be demonstrated to be from the 2:0 constitutional CNV genotype because they have somatically acquired gain of chromosome 1q (three copies) yet are two copies with heterozygous SNPs at the 1q21.1 CNV (see Supplementary  Fig. 7b, c for details) . These findings are consistent with the hypothesis that two copies in 'cis' (same chromosome) behave differently to two copies in 'trans' (different chromosomes). Therefore, we propose a model whereby NBPF23 expression is decreased when copies are in the cis configuration as opposed to the trans configuration. Importantly, however, even when the two-copy samples are not clustered in this manner, a statistically significant difference in transcript levels is observed between the two-and three-copy samples (P 5 0.001). Finally, we analysed expression of NBPF23 in a panel of 28 normal fetal and adult tissues (Fig. 2d) . We observed the highest transcript levels in fetal brain and fetal sympathetic ganglia from early gestation (13-22 weeks), consistent with NBPF23 being expressed in early sympathicoadrenal neurodevelopment.
NBPF genes were identified after the founding member, NBPF1, was determined to be disrupted by means of a constitutional chromosomal translocation in a neuroblastoma patient 3, 4 . Subsequent scans of the genome identified three clusters of NBPF genes on chromosome 1 within areas of segmental duplication. The encoded proteins are recently evolved and primate-specific, share significant homology and contain highly conserved domains of unknown function Table 1 LETTERS (DUF1220) that are thought to be neuronal-specific 3, 20 . Constitutional deletions disrupting NBPF genes have been implicated in schizophrenia [10] [11] [12] and autism 10 , and rare recurrent structural variants just upstream of the CNV identified in this study have also been reported in a variety of phenotypes including mental retardation, autism and congenital anomalies 21 . Although the specific functions of NBPF genes are not known, recently evolved genes may be involved in cancer predisposition owing to a lack of selective pressure 12 . Expression of NBPF1 was recently shown to suppress anchorageindependent growth 4 . Conversely, overexpression of NBPF transcripts has been reported in several cancers including sarcomas 22 and nonsmall-cell lung cancer 23 . A challenge for the field is to design experiments that clearly distinguish these highly homologous transcripts and define specific disease-causal mechanisms.
Neuroblastoma develops from the malignant transformation of partially committed sympathicoadrenal neuroblasts during fetal or early childhood development. We previously identified the ALK gene as the major familial neuroblastoma predisposition gene 1 and showed that common SNP variations at 6p22 and 2q35 are associated with sporadic neuroblastma 1,2 . In our current study, we show that a common CNV at 1q21.1 likewise contributes to neuroblastoma susceptibility, and that this CNV leads to altered expression of NBPF23, a previously unknown NBPF transcript. These data provide evidence for a specific CNV predisposing to human cancer, and ongoing efforts will define remaining susceptibility variants in the human genome associated with neuroblastoma.
METHODS SUMMARY
A multi-phase GWAS of CNVs in neuroblastoma was performed. A discovery set of 846 Caucasian neuroblastoma patients and 803 Caucasian healthy controls were genotyped using a 550K SNP array and CNV profiles were generated 16, 24 , providing a copy number state for each SNP on the array. Association with neuroblastoma was assessed at 531,689 individual SNPs on autosomes using Fisher's exact test on the binary comparison of 'deletion versus no deletion' or 'duplication versus no duplication'. A genome-wide significance threshold was set at P 5 1.0 3 10 27 and replication of significant findings was assessed using two independent replication sets, the first consisting of 363 Caucasian neuroblastoma cases and 1,139 Caucasian controls and the second of 232 Caucasian neuroblastoma cases and 2,218 Caucasian controls. Matched tumour DNA from a, Quantitative PCR validation of 1q21.1 CNV states shows 100% agreement with SNP genotyping data. Box and whisker plot is shown for 0 copies (n 5 10), 1 copy (n 5 16), 2 copies (n 5 12), 3 copies (n 5 6) and .3 copies (n 5 2). Lower and upper whiskers (error bars) indicate 10th and 90th percentiles respectively. b, Fluorescent in situ hybridization (FISH) validation of 1q21.1 deletion. Shown are metaphase spreads from lymphoblastoid cell lines established from an individual with the normal two copies (left) and an individual with hemizygous deletion (right). Red arrows: BAC RP4-790G17, which maps just outside of the deletion CNV from 148,424,830-148,557,655 bp (two copies in both individuals). Green arrows: fosmid W12-1967b11, which maps within the deleted region from 147,382,742-147,420,968 bp (one copy in individual with hemizygous deletion). c, Box and whisker plot showing correlation between CNV state and NBPF23 transcript levels demonstrated using real-time quantitative reverse transcriptase PCR in 18 neuroblastoma samples: 1 copy (n 5 5), 2 copies (low, n 5 4), 2 copies (high, n 5 3), 3 copies (n 5 5) and .3 copies (n 5 1). Lower and upper whiskers (error bars) indicate 10th and 90th percentiles respectively. Two-copy samples clustered into two distinct groups consistent with expression difference based on whether copies are in cis (2:0 CNV genotype) or trans (1:1 CNV genotype); see text for details. d, Expression of NBPF23 in normal fetal and adult tissues using real-time quantitative reverse transcriptase PCR showed highest levels in fetal brain (13-22 weeks) and fetal sympathetic ganglia samples (18-22 weeks), which were collected at the Children's Hospital of Philadelphia.
226 cases was genotyped to evaluate whether observed deletions were constitutional or somatically acquired rearrangements in the blood. An independent set of 713 trios with no reported incidence or history of cancer was genotyped and used to establish heritability of significant CNVs. Inherited CNVs were validated by quantitative real-time PCR and fluorescent in situ hybridization. Association with clinical and biological co-variates was assessed on the combined set of 1,441 neuroblastoma cases with available annotation. PCR amplification of cDNA from fetal brain and neuroblastoma cell lines was performed to identify a novel 1q21.1 transcript; products from these PCR reactions were sequenced and aligned to the human genome using BLAT 25 . Similarity to known NBPF transcripts was detected using Blastn 19 . Expression of the novel NBPF transcript was assessed using real-time quantitative reverse transcriptase PCR.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
